NEW YORK (GenomeWeb) – Piper Jaffray today initiated coverage of molecular cancer diagnostic firm Trovagene with an Overweight rating and a $6.25 price target.
NEW YORK (GenomeWeb) – Piper Jaffray today initiated coverage of molecular cancer diagnostic firm Trovagene with an Overweight rating and a $6.25 price target.
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?
Login Now.
Don't have a GenomeWeb or 360Dx account?
Register for Free.